B cell chronic lymphocytic leukemia (CLL) is the most common subtype of adult leukemia and is associated with profound secondary immunodeficiency. SARSCoV-2 infection has been a significant cause of morbidity and mortality (Mato et al., 2020; Pagano et al., 2021), and immunological responses against SARSCoV-2 vaccines are impaired (Fendler et al., 2021) in patients with CLL. In particular, reduced rates of seroconversion and antibody titer have been reported (Parry
et al., 2021; Greenberger et al., 2021; Herishanu et al., 2022) and associate with
reduced serum immunoglobulin level or use of medication such as Bruton tyrosine
kinase inhibitors or anti-CD20 antibodies (Parry et al., 2021; Herishanu et al.,
2022). However, questions regarding optimal immune protection remain unresolved, and these include the potential for additional vaccine doses to increase
seroconversion rate, potential humoral and cellular immune protection against
Omicron, and the impact of vaccine delivery on breakthrough infection rate and clinical outcome.
This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.
Parry, H., Bruton, R., Roberts, T., McIlroy, G., Damery, S., Sylla, P., Dowell, A., Tut, G., Lancaster, T., Bone, D., Willett, B., Logan, N., Scott, S., Hulme, S., Jadir, A., Amin, U., Nicol, S., Stephens, C., Faustini, S., Al-Taei, S., Richter, A., Blakeway, D., Verma, K., Margielewska-Davies, S., Pearce, H., Pratt, G., Zuo, J., Paneesha, S. & Moss, P. 2022, 'COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia', Cancer Cell, 40(6), pp. 584-586. http://dx.doi.org/10.1016/j.ccell.2022.05.001